Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors

A case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Lei Deng, Janaki N. Sharma, Elizabeth Ravera, Balazs Halmos, Haiying Cheng

Research output: Contribution to journalArticle

Abstract

Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalLung Cancer: Targets and Therapy
Volume9
DOIs
StatePublished - Jan 1 2018

Fingerprint

Lung Neoplasms
Hypersensitivity
Delayed Hypersensitivity
CH5424802
Neoplasms

Keywords

  • Alectinib
  • Brigatinib

ASJC Scopus subject areas

  • Oncology

Cite this

@article{9e1b4c9a0ab940109d89ec8fc4562fe0,
title = "Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: A case of successful switch to an alternative ALK inhibitor and systematic review of the literature",
abstract = "Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.",
keywords = "Alectinib, Brigatinib",
author = "Lei Deng and Sharma, {Janaki N.} and Elizabeth Ravera and Balazs Halmos and Haiying Cheng",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/LCTT.S173948",
language = "English (US)",
volume = "9",
pages = "73--77",
journal = "Lung Cancer: Targets and Therapy",
issn = "1179-2728",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors

T2 - A case of successful switch to an alternative ALK inhibitor and systematic review of the literature

AU - Deng, Lei

AU - Sharma, Janaki N.

AU - Ravera, Elizabeth

AU - Halmos, Balazs

AU - Cheng, Haiying

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

AB - Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

KW - Alectinib

KW - Brigatinib

UR - http://www.scopus.com/inward/record.url?scp=85059043297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059043297&partnerID=8YFLogxK

U2 - 10.2147/LCTT.S173948

DO - 10.2147/LCTT.S173948

M3 - Article

VL - 9

SP - 73

EP - 77

JO - Lung Cancer: Targets and Therapy

JF - Lung Cancer: Targets and Therapy

SN - 1179-2728

ER -